BioSpace News Archive

Manufacturing is Expected to Contract in 2020; Revenue to Decrease 10.3%; Capital Expenditures to Decrease 19.1%; Capacity Utilization Currently at 75.9%

The American Academy of Orthopaedic Surgeons expanded a list of specific tests and procedures that orthopaedic surgeons and patients should question as part of the Choosing Wisely® campaign, an initiative of the ABIM Foundation.

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that preclinical research on two of its drug candidates, uproleselan and GMI-1359, will be shared at the American Association for Cancer Research (AACR) Annual Meeting 2020, which will now be held virtually from June 22-24.

Lifestyle choices continue to be a leading risk factor for a wide array of health conditions, including lowered hormone levels and subsequent sequalae.

Vital funds will save thousands of world-class researchers from having to walk away from Canada and their lifesaving work on COVID-19, cancer and other diseases and help them ramp up their labs after the pandemic

Clinical Trials Research® (CTR), located in Lincoln and Sacramento, has recently launched a new campaign entitled “Become a Medical Hero during Shelter in Place” and is seeking patients to participate in research studies testing investigational medications.

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that the journal Frontiers of Immunology (“Frontiers”) released the results of the exploratory study on Treatment on a cohort of confirmed COVID-19 cases in Wuhan

Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations

Financial Results. Net losses from the same quarter last year decreased 11.7%, from $1,135,420 in Q1 2019 to $1,002,868 in Q1 2020, primarily attributed to a decrease in selling, general, and administration expenses.

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months ended March 31, 2020.